Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and ...
Artificial intelligence (AI) Enhanced service robotics is rapidly shifting from experimental prototypes toward real-world commercial deployment. The shift is driven by labor shortages, rising ...
The Alliant 3 awards build on GSA’s long-running Alliant contract lineage. In 2017, GSA selected 80 companies for the small business track of a potential 10-year, $15 billion Alliant 2 IT GWAC vehicle ...
Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results